EGFR and neoplasm: Moreover, the resistance to gefitinib in unmethylated PC-9 tumor cells having EGFR exon19 deletion was bypassed by using a combined treatment of 5-aza-2’-deoxy cytidine (5-aza-CdR) and gefitinib, thus boosting the growth inhibitory effects and leading to the activation of caspases (42).